ArticleScientific reports2025
Efficacy and fibrinogen correlations of defibrinogen therapy in idiopathic sudden sensorineural hearing loss.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Combination of Electroacupuncture and Medication for Patients With Tinnitus Associated With Idiopathic Sudden Sensorineural Hearing Loss: Protocol for a Prospective Randomized Controlled Trial.JMIR research protocols · 2025Article
- Current Role of the Nonsteroid Treatment of Idiopathic Sudden Sensorineural Hearing Loss (ISSNHL): A Narrative Review.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
This study aimed to assess the efficacy of Defibrinogen (DF) therapy in addressing total deafness of idiopathic sudden sensorineural hearing loss (TD-ISSNHL) and investigate the relationship between fibrinogen levels and auditory outcomes. A total of 342 cases of TD-ISSNHL were retrospectively analyzed, with patients divided into two main groups: an experimental group receiving batroxobin in conjunction with Ginaton and glucocorticoids, and a control group receiving Ginaton and glucocorticoids only. Auditory outcomes on the 10th day and the 14th day were analyzed and compared across these groups. Subsequently, the correlation between plasma fibrinogen and prognosis were analyzed within these groups. By the 10th day, the overall efficacy rates in the experimental groups were significantly higher than that in the control group (P = 0.039). Patients extending DF therapy to the 14th day showed a substantial improvement in the overall efficacy rate, from 50.98 to 82.35%. Additionally, significant differences in fibrinogen levels were observed on day 1, day 3, and day 5 ± 1 between the recovery and non-recovery groups (P = 0.013, P = 0.024, P = 0.005). Spearman's rank correlation analysis indicated weak negative correlations between fibrinogen levels on day 1 and day 3 and hearing improvement, while the level on day 5±1 had a moderate negative correlation. Throughout the follow-up period, no major complications were observed. The study findings suggest that batroxobin therapy not only improves hearing recovery but also maintains plasma fibrinogen at a low and safe level. In addition, sustained low fibrinogen level throughout treatment serves as a predictor for better prognosis in TD-ISSNHL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.